Kalaris Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for retinal diseases. It is focusing on developing TH103, a novel anti-VEGF agent targeted at treating neovascular and exudative retinal diseases. The company is headquartered in Palo Alto, CA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
6
Frequently Asked Questions
What is Market Cap of AlloVir Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. AlloVir Inc market cap is $89.21M.
What is the 52-week high for AlloVir Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. AlloVir Inc 52 week high is $24.15 as of October 25, 2025.
What is the 52-week low for AlloVir Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. AlloVir Inc 52 week low is $2.14 as of October 25, 2025.
What is the PE ratio of AlloVir Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. AlloVir Inc’s P/E ratio is -0.63.
What is the Price-to-Book ratio of AlloVir Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. AlloVir Inc P/B ratio is 1.6796.
What is the 50-day moving average of AlloVir Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. AlloVir Inc 50-day moving average is $4.56.
